Latest Editas Medicine News & Updates

See the latest news and media coverage for Editas Medicine. We track all announcements, press releases, and industry mentions in real time, all in one place.

Editas Medicine

Gene editing company developing CRISPR medicines

editasmedicine.com

Headquarters: Cambridge, United States
Founded year: 2013
Company type: Public company
Number of employees: 200–500
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about Editas Medicine

In short: Editas Medicine progressed its in vivo CRISPR pipeline, reported positive trial data for reni-cel, and executed a 65% workforce reduction.

Company announcements

September 9 Editas Medicine

Editas Medicine grants stock options to new CMO Daniel Ory

The board approved a grant of up to 950,000 shares at $3.03 per share as an inducement for his employment, vesting over four years.

September 8 Editas Medicine

Editas Medicine appoints Dan Ory as Chief Medical Officer

Dr Ory leads clinical strategy and trials for the company genome editing programs across multiple therapeutic areas.

August 5 Editas Medicine

Editas Medicine reports Q2 2026 results and EDIT-401 progress

EDIT-401 is on track for CTN submission this month, with preclinical data showing ~90% LDL-C reduction; company raised $125M and extends cash runway into 2H 2028.

June 11 Editas Medicine

Editas Medicine reports EDIT-401 reduces LDL-C in NHPs

A single dose achieved over 90% mean reduction in LDL-C, ApoB, and Lp(a) in non-human primates.

Media coverage

September 8 Yahoo Finance

Editas Medicine (NASDAQ:EDIT) Stock Price Up 10.5% - Time to Buy?

Editas Medicine (NASDAQ:EDIT) Trading 10.5% Higher - Here's Why...

Never miss news about Editas Medicine

Track Editas Medicine and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.